Advertisement

Kidney Cancer and Its Treatment

Chapter
  • 179 Downloads

Abstract

Renal cell carcinoma (RCC) is the most common type of primary kidney neoplasm. Though most masses are found incidentally and are asymptomatic, patients can still present with the classic triad of RCC – flank pain, hematuria, and palpable abdominal mass. Cross-sectional imaging with computed tomography (CT) or magnetic resonance imaging (MRI) is most helpful for staging and diagnosis; however, the role of renal biopsy is expanding. Many patients, especially elderly and the comorbid, can be placed on active surveillance. Focal therapy ablation is utilized in some patients; however, surgery continues to be the gold standard therapy for renal mass. Partial nephrectomy is offered to appropriately selected patients with stage I tumors, while radical nephrectomy is reserved for patients with large and/or anatomically complex renal mass. Radiation and chemotherapy play a limited role in localized RCC treatment. Targeted therapy and immunotherapy are enjoying expanding indications in the RCC space.

Keywords

Kidney cancer Active surveillance Focal ablation Partial nephrectomy Radical nephrectomy Adjuvant therapy Immunotherapy 

References

  1. 1.
    Ljungberg B, Campbell SC, Choi HY, Cho HY, Jacqmin D, Lee JE, Weikert S, Kiemeney LA. The epidemiology of renal cell carcinoma. Eur Urol. 2011;60(4):615–21.CrossRefGoogle Scholar
  2. 2.
    Kutikov A, et al. Renal mass biopsy: always, sometimes, or never? Eur Urol. 2016;70(3):403–6.CrossRefGoogle Scholar
  3. 3.
    Kim JH, Li S, Khandwala Y, Chung KJ, Park HK, Chung BI. Association of prevalence of benign pathologic findings after partial nephrectomy with preoperative imaging patterns in the United States from 2007 to 2014. JAMA Surg. 2019;154(3):225–31.CrossRefGoogle Scholar
  4. 4.
    Rini BI, McKiernan JM, Chang SS, et al. Kidney. In: Amin MB, editor. AJCC cancer staging manual. 8th ed. New York: Springer; 2017. p. 739.Google Scholar
  5. 5.
    Ristau BT, et al. Active surveillance for small renal masses: when less is more. Eur Urol Focus. 2016;2(6):660–8.CrossRefGoogle Scholar
  6. 6.
    Ginzburg S, et al. Focal ablation therapy for renal cancer in the era of active surveillance and minimally invasive partial nephrectomy. Nat Rev Urol. 2017;14:669–82.CrossRefGoogle Scholar
  7. 7.
    Colombo JR Jr, Haber GP, Jelovsek JE, Lane B, Novick AC, Gill IS. Seven years after laparoscopic radical nephrectomy: oncologic and renal functional outcomes. Urology. 2008;71(6):1149.CrossRefGoogle Scholar
  8. 8.
    Kim SP, et al. Collaborative review of risk benefit trade-offs between partial and radical nephrectomy in the management of anatomically complex renal masses. Eur Urol. 2017;72(1):64–75.  https://doi.org/10.1016/j.eururo.2016.11.038.CrossRefPubMedGoogle Scholar
  9. 9.
    Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol. 2009;182(3):844–53.  https://doi.org/10.1016/j.juro.2009.05.035.CrossRefPubMedGoogle Scholar
  10. 10.
    Kjaer M, Frederiksen PL, Engelholm SA. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys. 1987;13(5):665.CrossRefGoogle Scholar
  11. 11.
    Oudard S, etal. GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales). Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d’Etudes des Tumeurs Uro-Génitales) study. J Urol. 2007;177(5):1698.Google Scholar
  12. 12.
    McDermott DF, Lee JL, Szczylik C, et al. Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma: results from cohort A of KEYNOTE-427. J Clin Oncol. 2018;36S:ASCO #4500.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2021

Authors and Affiliations

  1. 1.Department of Surgical OncologyFox Chase Cancer CenterPhiladelphiaUSA

Personalised recommendations